| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1550 | |
| Phytochemical name or plant extracts | Rhizoxin | |
| PMID | 1450065 | |
| Literature evidence | Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. | |
| IUPAC name | (1S,3S,5R,8S,10S,11R,13R,14E,16R,17R)-10-hydroxy-8-[(2S,3R,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.03,5.011,13]henicos-14-ene-6,19-dione | |
| Phytochemicals’ class or type of plant extracts | Lactone | |
| Source of phytochemicals or plant Extracts | Rhizopus chinensis | |
| Geographical availability | NA | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Skin cancer, Lung cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | In the present study, cytotoxic activity was observed in human tumour cell lines in vitro at very low concentrations (+/- 10(-10) M) particularly against melanoma, colon, renal, non-small cell and small cell lung cancer. In vivo antitumour activity was demonstrated in murine P388 and L1210 murine leukaemias, solid tumour models B16 melanoma and M5076 sarcoma, and in 5 out of 9 human solid tumour xenografts: LOX melanoma, MX-1 breast cancer, non-small cell lung cancer A549, and small cell lung cancers LXFS 605 and LXFS 650. | |
| Cell line/ mice model | B16 melanoma, M5076 sarcoma, LOX melanoma, MX-1 breast cancer, A549 | |
| Additional information | In addition, rhizoxin caused minor responses in three heavily pretreated patients with recurrent breast cancer. Phase II clinical trials will start soon within the framework of the EORTC and CRC. | |
| PubChem ID | 6437358 | |
| Additional PMIDs | 25114240 1462165 8562349 | |
| Additional sources of information | NA | |
| Safety | The LD10 value of rhizoxin after a single intravenous injection was 2.8 mg/kg (8.4 mg/m2). One-tenth of the mouse equivalent LD10 (0.84 mg/m2), the starting dose for clinical phase I studies, was considered to be safe in rats. |